<div id="readability-page-1">We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) stands against the other weight loss stocks.<h2>The Revolution in Obesity Treatment: Opportunities and Challenges of GLP-1 Medications</h2>Most people have at some point sought to include weight loss and physical exercise in their daily life. The weight loss and fitness market is quite substantial worldwide since improving one’s fitness can have direct physical and psychological benefits. Over one billion people worldwide—650 million adults, 340 million adolescents, and 39 million children—are obese, according to the WHO. A novel class of weight-loss medications that don’t include strict exercise regimens or diets seems to be revolutionary. People who are overweight or obese can lose 15% to 20% of their body weight with the aid of these ground-breaking medications. According to Andy Acker, portfolio manager at Janus Henderson Investors, “This may be the largest opportunity we’ve ever seen in the pharmaceutical industry.” Weight-loss medications are undoubtedly well-liked. Investors are drawing comparisons between the leader in artificial intelligence chips and the US pioneer in weight-loss drugs.Given this increase in demand, Morgan Stanley Research has raised its forecast for the worldwide obesity medication market from $77 billion to $105 billion by 2030. Branded obesity medications brought approximately $6 billion in 2023.According to Forbes, the most prescribed Glucagon-Like Peptide-1 GLP-1 agonist in 2023 was Semaglutide, the market leader for obesity medications and the generic form of Ozempic, Wegovy, and Rybelsus. It accounted for almost 88% of all new prescriptions. At present, the FDA has approved just three GLP-1 medications for weight control: tirzepatide, liraglutide, and semaglutide.By 2030, the GLP-1 market is expected to grow to $100 billion, driven equally by obesity and diabetes, according to JP Morgan Research. Thirty million GLP-1 users, or around 9% of the population, may be in the US by 2030. The rising demand for obesity drugs will have a broad effect, helping industries like biotech but creating challenges for others like the food and beverage industry.According to Chris Schott, a Senior Analyst specializing in the U.S. Diversified Biopharma industry,<blockquote> “GLP-1s have been used to treat T2D since 2005, starting with the approval of Byetta, with follow-on products continually improving on efficacy. The most recent, Ozempic and Mounjaro, offer significant advantages over previous products and have accelerated class growth,” “Indeed, the newest generations of GLP-1s and combos lead to 15-25+% weight loss on average, well above prior generations of products.” </blockquote>Some are praising the most recent generation of GLP-1 pharmaceuticals as “miracle drugs” for the treatment of obesity. However, because GLP-1s are expensive and have limited insurance coverage, not all obese people can use them. According to Jonathan Gruber, a professor of economics and the chairman of MIT’s economics department, the annual cost of treating 40% of obese Americans at the current rate—roughly $15,000 per person—would surpass $1 trillion. That’s almost the same as the government spends on the entire Medicare program. That’s a staggering figure.<h2>GLP-1 Medications: Balancing Rising Demand, Shortages, and Market Potential</h2>According to a study released in the Annals of Internal Medicine, the use of GLP-1 medications, including semaglutide, for weight loss has increased over the last ten years, while it has dropped by about 10% among those with type 2 diabetes. The researchers warn that the ensuing extended drug scarcity may limit the treatments’ availability to diabetics. Dr. Yee Hui Yeo, a clinical fellow in Cedars-Sina’s Karsh Division of Gastroenterology and Hepatology, emphasized that it is crucial to ensure that diabetic patients have access to GLP-1 therapies as the demand for obesity medications increases.According to the FDA, growing demand is the cause of the shortages. The European Medicines Agency warned that the GLP-1 medicine shortage is a “major public health concern” that is unlikely to be resolved in 2024, indicating that the shortages affect more than only the US. According to NPR, shortages have made it difficult for those with diabetes to get their prescriptions, and some have had to reduce the medications they can use.The potential of GLP-1 medications, which were first created to treat diabetes but are currently being used to treat obesity, was covered by the panelists on “Weighing the Future of Obesity Drugs,” which included Julia Angeles of Baillie Gifford, Debra Netschert of Jennison Investments, and Gentry Lee of Fayez Serofim. Netschert highlighted ongoing efforts to further reduce injection frequency and minimize adverse responses, as well as the development of GLP-1 medicine delivery from weekly dosages to multiple daily injections. Despite their exceptional efficacy, Netschert noted that due to supply limits, 1.5 million of the 110 million eligible patients in the US are now receiving therapy with GLP-1 medications. In their disagreement over who should foot the bill, Netschert pointed to significant insurance and Medicare/Medicaid reimbursements, while Angeles asserted that most patients pay cash. According to Netschert, up to 700 million people globally might require these medications outside of American borders. Notably, the panel found that GLP-1 medications were approved more quickly in the United Kingdom than in any other country, indicating their perceived value. The UK payors are generally stringent.Since the market for obesity medications is still in its infancy, it would be a good idea to add several weight reduction stocks to your watchlists.<h2>Our Methodology </h2>For this list, we scanned through holdings of weight loss ETFs and online rankings to form an initial list of 20 weight loss stocks. From that list, we picked 12 stocks with the highest number of hedge fund holders as of Q3 2024, based on data tracked by the Insider Monkey database. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them.Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points ().<div id="attachment_1207526"><img src="https://imageproxy.pbkrs.com/https://imonkey-blog.imgix.net/blog/wp-content/uploads/2023/10/18235859/GPCR-insidermonkey-1697687936439.jpg/query-YXV0bz1mb3J0bWF0JmV4cGlyZXM9MTc2NTg0MzIwMCZmaXQ9Y2xpcCZoZWlnaHQ9MjY5JndpZHRoPTQ4MA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="830" height="465" original-src="https://imageproxy.pbkrs.com/https://imonkey-blog.imgix.net/blog/wp-content/uploads/2023/10/18235859/GPCR-insidermonkey-1697687936439.jpg/query-YXV0bz1mb3J0bWF0JmV4cGlyZXM9MTc2NTg0MzIwMCZmaXQ9Y2xpcCZoZWlnaHQ9MjY5JndpZHRoPTQ4MA"/>A scientist in a lab coat observing a beaker with colored liquid as it bubbles and hisses.</div><h3>Structure Therapeutics Inc. (NASDAQ:GPCR)</h3>Number of Hedge Fund Holders: 40 Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage biopharmaceutical company developing oral small-molecule drugs for chronic diseases like obesity, type-2 diabetes, and cardiopulmonary conditions. Its lead product candidate, GSBR-1290, targets type-2 diabetes and obesity, while other pipeline candidates focus on idiopathic pulmonary fibrosis and other pulmonary diseases. The company’s drugs are designed to be more accessible and convenient than traditional injectable therapies. Its target market includes patients seeking effective treatments for chronic conditions.Structure Therapeutics Inc. (NASDAQ:GPCR), considered one of the best weight loss stocks, is advancing its oral GLP-1 receptor agonist, GSBR-1290, through Phase 2b studies, with the Phase 2 ACCESS II study set to begin by the end of 2024. These studies aim to assess GSBR-1290’s efficacy and safety in treating obesity and overweight adults. The corporation is also developing other candidates, including amylin receptor agonists, GIPR selective agonists, and GLP-1R/GIPR combinations, along with ANPA-0073 for weight loss and idiopathic pulmonary fibrosis.As of Q3 2024, Structure Therapeutics Inc. (NASDAQ:GPCR) had $915.3 million in cash and investments, sufficient to fund operations and key milestones through 2027, excluding Phase 3 studies. Research and development expenses rose to $32.6 million, up from $17.5 million in Q3 2023 which was driven by program advancements and increased personnel. General and administrative expenses increased to $13.2 million from $8.6 million due to higher employee and professional service costs. The company also reported a net loss of $34.0 million, compared to $23.9 million in Q3 2023, including a $6.0 million non-cash share-based compensation expense.Wall Street analysts hold a consensus Strong Buy rating on the stock, with an average 12-month price target of $88.88. The price target range includes a high forecast of $118.00 and a low of $65.00. The average target represents a 156.18% increase from the current price of $34.70.Overall GPCR ranks 11th on our list of the best weight loss stocks to buy according to hedge funds. While we acknowledge the potential of GPCR as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than GPCR but that trades at less than 5 times its earnings, check out our report about the .Disclosure: None. This article is originally published at Insider Monkey.Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal! The whispers are turning into roars. Artificial intelligence isn’t science fiction anymore. It’s the revolution reshaping every industry on the planet. From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards. Here’s why this is the prime moment to jump on the AI bandwagon: Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory. Imagine every sector, from healthcare to finance, infused with superhuman intelligence. We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything. This isn’t a maybe – it’s an inevitability. Early investors will be the ones positioned to ride the wave of this technological tsunami. Ground Floor Opportunity: Remember the early days of the internet? Those who saw the potential of tech giants back then are sitting pretty today. AI is at a similar inflection point. We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon. This is your chance to get in before the rockets take off! Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation. AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries. The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust. As an investor, you want to be on the side of the winners, and AI is the winning ticket. The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI. From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field. This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements. By investing in AI, you’re essentially backing the future. The future is powered by artificial intelligence, and the time to invest is NOW. Don’t be a spectator in this technological revolution. Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation. This isn’t just about making money – it’s about being part of the future. So, buckle up and get ready for the ride of your investment life! Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!) The AI revolution is upon us, and savvy investors stand to make a fortune. But with so many choices, how do you find the hidden gem – the company poised for explosive growth? That’s where our expertise comes in. We’ve got the answer, but there’s a twist… Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap. That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade! Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity. This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors. It’s like having a race car on a go-kart track. They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field. Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel. We want to make sure none of our valued readers miss out on this groundbreaking opportunity! That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%. For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal! Here’s why this is a deal you can’t afford to pass up: • Access to our Detailed Report on this Game-Changing AI Stock:Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential. • 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan. • One free upcoming issue of our 70+ page Quarterly Newsletter:A value of $149 • Bonus Reports:Premium access to members-only fund manager video interviews • Ad-Free Browsing:Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity. • 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked. Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment. Here’s what to do next: 1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29. 2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months. 3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee. Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future! Subscribe Now! No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later! Brace yourself. There’s no question that thanks to Washington’s disastrous policies – and out-of-control spending – the outlook for the U.S. economy now appears dire. And with the U.S. national debt now rising by a staggering $1 trillion every 100 days…there are no easy solutions to help get the nation back on track. While Jay Powell and the Biden-Harris White House sweat out a federal debt that has reached $35.5 trillion – and climbing – many investors have raced to the sidelines with their cash. But the truly savvy investors laugh while Jay Powell frets, because they understand that this ridiculous spending has also triggered a nearly unprecedented bull market for gold. Just look at this chart for the yellow metal. <img src="https://imageproxy.pbkrs.com/https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2024/12/16074714/Gold-chart-768x469.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="768" height="469" original-src="https://imageproxy.pbkrs.com/https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2024/12/16074714/Gold-chart-768x469.png"/> After testing the $2,000/ounce mark in August 2020 and February 2022, gold traded down to near $1,600/ounce in October 2022. Since then, gold prices have been on an absolute tear and currently sit above $2,600/ounce, a $1,000/oz increase in just two short years. But the surge in gold prices that we’ve seen over the past few years could pale in comparison to what’s on the horizon. As shocking as it may sound, with no end in sight for the Fed’s money printing, we could see the price of gold increase by many multiples in the years ahead. With soaring inflation, the dollar stands to lose more and more of its value, which means you’ll need a lot more dollars to buy gold. According to legendary investor Peter Schiff, today’s seemingly-high gold price of $2,600/oz. “could soar to $26,000/oz. — or even $100,000/oz. There’s no limit because gold isn’t changing — it’s the value of the dollar that’s decreasing.”[i] Meanwhile, as profitable as gold has been, select gold mining stocks have really kicked into high gear, handing investors even bigger profits. Click to continue reading… </div>

GPCR

Structure Therapeutics Inc. (NASDAQ:GPCR) is highlighted as a potential top weight loss stock amid rising demand for GLP-1 medications, which have shown significant efficacy in weight loss. The global obesity medication market is projected to grow substantially, with Morgan Stanley Research increasing its forecast. However, the rising demand has led to shortages, impacting access for diabetic patients. Experts emphasize the need for continued innovation in GLP-1 therapies while addressing supply challenges. The market's potential is significant, but the high costs and limited insurance coverage pose barriers for many obese individuals.

insidermonkey

Structure Therapeutics

Nasdaq

THDB

HYBIO

Schroders Plc

Morgan Stanley

U.S. Global Investors

BEST

Eli Lilly

AstraZeneca

STANLEY

Novo Nordisk AS

Is Structure Therapeutics Inc. (GPCR) the Best Weight Loss Stock to Buy Now According to Hedge Funds?